Use of anakinra in severe COVID-19: a case report

Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/41555

Registro completo de metadados

Campo DC	Valor	Idioma
dc.creator	Filocamo, Giovanni	-
dc.creator	Mangioni, Davide	-
dc.creator	Tagliabue, Paola	-
dc.creator	Aliberti, Stefano	-
dc.creator	Costantino, Giorgio	-
dc.creator	Minoia, Francesca	-
dc.creator	Bandera, Alessandra	-
dc.date.accessioned	2020-06-24T13:30:26Z	-
dc.date.available	2020-06-24T13:30:26Z	-
dc.date.issued	2020-07	-
dc.identifier.citation	FILOCAMO, G. et al. Use of anakinra in severe COVID-19: a case report. International Journal of Infectious Diseases, [S.l.], v. 96, p. 607-609, July 2020.	pt_BR
dc.identifier.uri	https://www.sciencedirect.com/science/article/pii/S1201971220303337	pt_BR
dc.identifier.uri	http://repositorio.ufla.br/jspui/handle/1/41555	-
dc.description.abstract	Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).	pt_BR
dc.language	en_US	pt_BR
dc.publisher	Elsevier	pt_BR
dc.rights	restrictAccess	pt_BR
dc.source	International Journal of Infectious Diseases	pt_BR
dc.subject	Anakinra	pt_BR
dc.subject	COVID-19 - Treatment	pt_BR
dc.title	Use of anakinra in severe COVID-19: a case report	pt_BR
dc.type	Artigo	pt_BR
Aparece nas coleções:	FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:

Não existem arquivos associados a este item.